Development and application of novel imaging methods for observational studies and clinical trials
This group focuses on developing new imaging-based biomarkers for monitoring the early phases of neurodegenerative processes and, potentially, the response to disease-modifying treatments.
We combine multiple modalities, including MRI, PET, fluid-based markers and genetics, to clarify the biological processes leading to neurodegenerative conditions. Additionally, we leverage data from deeply phenotyped cohorts to investigate heterogeneity and protective factors in both typical aging and neurodegenerative conditions.
In alignment with MultiPark's strategic goals
- To develop early and differential diagnostics and prognostics (e.g. by developing methods for detecting therapeutic effects of novel interventions on neurodegeneration and plasticity during the early presymptomatic stages).
- To understand the origins and progression of neurodegenerative disease (e.g. by integrating pathophysiological studies, OMICS, artificial intelligence, and machine learning to derive new knowledge from state-of-the-art experimental models).
- Foster interdisciplinary collaborations increasing the dialogue between the development of imaging techniques and their applications to research on neurodegenerative diseases.
- Develop an educational environment where students and early-career researchers can learn how to approach a scientific question from both a technical and clinical perspective.
- Lecture series on Neuroimaging in Neurodegeneration explaining critical methodological aspects followed by showcasing applications of these methods to answer clinical questions.
- Yearly Neuroimaging in Neurodegeneration symposium, including both presentations of clinical advances as well as hands-on sessions on neuroimaging analysis for students and early-career researchers.